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This article represents the proceedings of a workshop at the 2003 annual meeting of the Research
Society on Alcoholism in Fort Lauderdale, FL. The workshop organizers/chairpersons were Chinnaswamy
Kasinathan and Paul Manowitz. The presentations were (1) Introduction to the field of proteomics, by Kent
Vrana; (2) Use of proteomics in the identification of urinary biomarkers for alcohol intake, by Chin-
naswamy Kasinathan, Paul Thomas, and Paul Manowitz; (3) Proteomics screening illuminates ethanol-
mediated induction of HDL proteins in macaques, by Kent Vrana, Randy Gooch, Travis Worst, Stephen
Walker, Aaron Xu, Peter Pierre, Heather Green, and Kathleen Grant; and (4) Proteomics applied to the
study of the liver, by Laura Beretta.
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THE PURPOSE OF this workshop, The Future of Pro-teomics in the Study of Alcoholism, was 2-fold: (1) to
present a review of proteomic methodologies that have
been relatively recently developed and (2) to provide some
examples of applications of these methods. The idea for
this workshop was developed approximately a year ago by
Chinnaswamy Kasinathan and Paul Manowitz, who were
trying to find a method to identify protein changes caused
by alcohol intake. As they began to discuss this research
project, they realized that the tremendous recent advances
in the field of proteomics offered excellent opportunities to
study alcoholism. Furthermore, their cursory survey of the
literature indicated that these recent advances in proteom-
ics have not been widely applied to alcoholism research.
In great part, the field of proteomics has relied on the
methodological advances of mass spectrometry. For exam-
ple, before the use of mass spectrometry to sequence pro-
teins, sequencing was performed with the Edman’s reac-
tion, which took approximately 12 hr per sample. The same
sequence determination can be obtained by mass spectrom-
etry in approximately a second, with far greater sensitivity.
Once sequences have been obtained, these sequences can
be compared with the databases of known sequences to
identify the proteins. In this regard, the sequencing of the
human genome has greatly facilitated the progress made in
proteomics.
Because of the very rapid growth in this area, there are
many proteomic facilities throughout the world. Therefore,
this workshop was particularly valuable for researchers who
do not have a mass spectrometer but might want to collab-
orate with a proteomic center to solve some of their scien-
tific problems in alcoholism. The topics that were ad-
dressed in this workshop included (1) identification of
biomarkers of alcohol intake, (2) delineation of biochemi-
cal pathways to understand alcohol’s effects, and (3) a study
of hepatic proteins, including a discussion of the Human
Proteome Organization.
INTRODUCTION TO THE FIELD OF PROTEOMICS
Kent Vrana
The completion of the human genome project and recent
advances in technology have provided the alcohol research
community with a wide array of new technologies. The flow
of genetic information provides us with (1) genomics—the
study of the sequence of the genetic material (the genome);
(2) transcriptomics—the characterization of the comple-
ment of messenger RNA molecules expressed in a tissue or
cell; (3) proteomics—examination of the proteins that are
synthesized by a cell, tissue, or organ; and even (4) metabo-
lomics—the collection of small molecule metabolites that
are indicative of health and disease (lipid mediators, signal
transduction molecules, and so on). This discussion is fo-
cused on the penultimate of these—proteomics.
The central premise of proteomics is that the complete
characterization of the proteins in a cell, tissue, or organ
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will provide insights into the status of the system. That is to
say, a detailed understanding of the levels, structures, ac-
tivities, and interactions of the proteins will serve as a
molecular correlate of the physiologic state of the system.
This is a particularly cogent point when one realizes that
the DNA and messenger RNA in a system do not, in fact,
directly represent the working aspects of the cell. For in-
stance, although a mutation, or polymorphism, within a cell
might be associated with a disorder, it is the altered level or
function of the encoded protein that actually determines
the result. So why is it that we bother to pursue genomic
(gene-sequencing) or transcriptomic (DNA microarrays)
studies? The answer is that we have the technologies to
perform the former studies, whereas characterization of the
complete proteome remains a technological hurdle. This
workshop provides an overview of aspects of this techno-
logical approach.
Proteomics can be divided into three major components
based on methodological considerations. Structural pro-
teomics is the study of the physical arrangement of amino
acids into second-, third-, and fourth-order relationships. In
essence, because structure determines function, this is the
most elemental level of proteomics. This field would typi-
cally use technologies such as x-ray crystallography and
NMR spectroscopy. Functional proteomics addresses the
actual physiologic activity of proteins, whether it be enzyme
activity, physiologic interactions between proteins, or inter-
actions with other environmental constituents (e.g., lipids
or nucleic acids). Enzyme activity assays, receptor binding,
and protein-protein interactions are examples of these ex-
perimental approaches. Finally, expression proteomics rep-
resents the emerging field of study that focuses on the
patterns of protein expression levels in health and disease.
It is this form of proteomics that is receiving the most
attention in recent years and that is the subject of the
papers presented in this symposium. Notably, this field of
study has been enabled by the advent of new high-
throughput technologies for separating proteins in time
and space (by using two-dimensional gel electrophoresis,
differential protein capture, or sophisticated liquid chro-
matography technologies) and their subsequent quantifica-
tion and identification (typically via mass spectrometry).
Although the presentations in this symposium focus on
medium- to high-throughput screening of expression pro-
teomics, we do not intend to suggest that multiplex analysis
of structural and functional proteomics is not possible or
that it is not equally important. In fact, the high-
throughput, robotic analysis of small molecule inhibitors
and activators of enzymes is the basis for much of the
pharmaceutical industry’s drug discovery program. In ad-
dition, efforts to catalog all of the structural motifs present
in the field of structural proteomics promise to dramatically
increase the speed and fidelity of computer protein mod-
eling and characterization.
Together, these rapidly evolving technologies for the
characterization of proteins promise to provide a wealth of
information on health and disease. Indeed, as was shown in
the subsequent presentations in this symposium, we are
already gaining new insights into the pathophysiology of
alcohol.
USE OF PROTEOMICS IN THE IDENTIFICATION OF
URINARY BIOMARKERS FOR ALCOHOL INTAKE
Chinnaswamy Kasinathan, Paul Thomas, and
Paul Manowitz
Alcoholism is a treatable disease (McCrady and
Langenbucher, 1996; Weinrieb and O’Brien, 1997). Fur-
thermore, early detection of high alcohol intake can result
in a reduction of alcohol intake and psychosocial problems
and in prevention of alcoholism. It is well known that
alcoholics often deny their drinking habit and are able to
hide their level of consumption. Therefore, a convenient
method to detect excessive ethanol intake, by itself or in
conjunction with other detection methods, would be help-
ful for monitoring alcoholics in treatment and for identify-
ing subjects who are at risk for alcoholism.
Biomarkers are being increasingly used to evaluate the
effectiveness of alcoholism treatment (Anton et al., 1999;
Chick et al., 1992; Johnson et al., 1996; Volpicelli et al.,
1997). However, research during the past 15 years has not
provided a perfectly valid biomarker. The most commonly
used biomarker tests—the carbohydrate-deficient trans-
ferrin and -glutamyl transpeptidase tests—are useful for
identifying individuals with alcohol problems, but they have
significant limitations (Lakshman et al., 2001; Litten et al.,
1995). Furthermore, these biomarkers do not identify alco-
hol problems for women as well as they do for men. In
addition, these tests perform well on adults but not on
adolescents with alcohol problems. It is clear that a more
valid biomarker is needed to prevent and treat alcohol
abuse and alcoholism in all groups. Also, the available
biomarkers are generally blood based and, therefore, have
the limitation of requiring phlebotomy.
To identify a urinary biomarker for alcohol intake, male
Sprague-Dawley rats were subjected to pair feeding with
regular Lieber-DeCarli liquid diets and a low-fat ethanol
diet (Dyets, Inc., Bethlehem, PA). Each control animal was
paired with an ethanol-treated animal so that the number
of calories consumed by the ethanol-treated rat was the
amount the control received on the following day. The
animals were initially fed with control diet for 2 days. Pair
feeding was started with 3% ethanol on day 3, 4% ethanol
on day 4, and 5% ethanol for the remaining 15 days of
treatment.
Analysis of the urine samples from ethanol-treated and
control rats was performed by using two-dimensional gel
electrophoresis with Coomassie blue staining. The two-
dimensional electrophoretic separation revealed the pres-
ence of several unique proteins that were present in the
urine of the ethanol-treated animals but were absent in the
urine of control animals. In one region of the two-
FUTURE OF PROTEOMICS IN THE STUDY OF ALCOHOLISM 229
dimensional gel of the urine from ethanol-treated animals,
there were two groups of proteins: one group contained
three proteins with a molecular weight of approximately 70
kDa separated by different isoelectric points, and another
group contained three proteins with a molecular weight of
approximately 66 kDa separated by different isoelectric
points. These 6 bands were very prominent and distinct and
have been observed in urine samples from 14 ethanol-
treated rats. The protein-stained spots were cut from the
gel as 3-mm cylindrical plugs and destained with several
changes of acetonitrile:water (6:4). These plugs were taken
to near dryness and rehydrated in ammonium carbonate
buffer containing modified trypsin. After overnight incuba-
tion at 37°C, the peptides resulting from trypsin hydrolysis
were recovered from the buffer and concentrated by se-
quential absorption and elution with ZipTips (Millipore
Corp., Bedford, MA). ZipTips are small quantities of
reverse-phase C-18 resin packed in pipet tips. Mass spectra
analysis of these peptides reveals the molecular weights of
the individual peptides, and these are allowed to fragment
in an additional mass-resolving part of the same mass
spectrometry (MS) instrument (MS-MS, i.e., tandem MS)
to yield fragmentation patterns of the peptides. The frag-
mentation patterns obtained by these MS-MS instruments
(LCQ DECA XP Ion Trap, Thermo Electron Corporation,
West Palm Beach, FL) are a rich source of information that
is dependent on the sequence of amino acids in the partic-
ular peptide. These complex fragmentation patterns are
then compared with databases of amino acid sequence
information that are derived from protein and DNA se-
quence databases. When there is a relatively good agree-
ment of the MS-MS data with the expected fragmentation
pattern of the peptide in the database, then it is reasonable
to assume that it is the same protein or a closely related
family member. It should be appreciated that this type of
so-called identification of the protein or proteins in a two-
dimensional gel spot is dependent both on the complete-
ness of the data in the database (including the absence of
errors) and on the quality of the MS-MS data. Clearly, if an
important concept hinges on the identification of a protein
spot, there should be some secondary support. For exam-
ple, recognition of the blotted spot by a specific antibody or
some property of its regulation of expression or unique
subcellular distribution would serve to build a consensus of
agreement as to its identity.
One of the bands, identified as transferrin by mass spec-
trometry, was present in urine from the ethanol-fed rat, but
not in that of the control rat. Additional studies are ongo-
ing to identify the other bands specific to the urine from
alcohol-treated animals.
The ultimate goal of this research is to apply what is
known from rats to the development of good urinary bi-
omarkers in humans as a measure of alcohol intake. This
would have particular application in many alcoholism treat-
ment facilities. The National Survey of Substance Abuse
Treatment Services (National Directory of Drug and Alco-
hol Abuse Treatment Programs, 2000) listed approximately
17,000 facilities that treated patients with substance abuse,
including alcoholism. The nature of these facilities varied
widely from very small solo practices to very large hospital
complexes and residential treatment centers. Many of these
facilities do not have easy access to phlebotomists on site.
Therefore, urinary tests are more convenient measures of
alcohol intake than blood tests in many of these facilities.
PROTEOMICS SCREENING ILLUMINATES ETHANOL-
MEDIATED INDUCTION OF HDL [HIGH-DENSITY
LIPOPROTEIN] PROTEINS IN MACAQUES
Kent Vrana, Randy Gooch, Travis Worst, Stephen Walker,
Aaron Xu, Peter Pierre, Heather Green, and
Kathleen Grant
Alcohol abuse and alcoholism remain serious societal
problems with wide-ranging effects on biochemistry, phys-
iology, and behavior. In this study, cynomolgus monkeys
(Macaca fascicularis) were used in an ethanol self-
administration protocol for proteomic serum profiling.
Surface-enhanced laser desorption ionization time-of-flight
(SELDI-TOF) mass spectrometry and other proteomic
methodologies were used to identify serum biomarkers of
the consumption of ethanol. Serum samples from monkeys
trained to self-administer ethanol (4% w/v prepared with
water only) were collected from the ethanol-naive state
through 9 months of heavy ethanol-consumption and then
into a period of enforced abstinence. Samples were sub-
jected to analysis on SELDI-TOF hydrophobic Protein-
Chips (Ciphergen Biosystems, Inc., Fremont, CA) to illu-
minate differentially expressed proteins. Potential
biomarkers were then identified by using one- and two-
dimensional polyacrylamide gel electrophoresis and subse-
quent trypsin digestion and mass spectroscopic fingerprint
identification of the excised bands of interest. On analysis
of SELDI-TOF mass spectra, two prominent serum pro-
teins, one at 27.9 kDa and another at 8.7 kDa, were ob-
served to be differentially expressed. Analysis of the 27.9-
and 8.7-kDa proteins by trypsin digestion fingerprinting
identified them as apolipoprotein AI and apolipoprotein
AII, respectively. Their correspondence with the SELDI-
TOF MS peak was verified with purified human apoli-
poprotein AI and AII proteins. Immunoblot analysis of
samples from individual animals confirmed that ethanol
consumption significantly increased apolipoprotein AII.
However, although apolipoprotein AI seemed to increase
after ethanol self-administration, wide interanimal variabil-
ity precluded a statistically significant finding. In agreement
with previous studies of human ethanol consumption, these
studies suggest that alcohol self-administration produces an
increase of lipoproteins associated with cardiovascular pro-
tective effects. These findings contribute further evidence
that it is the ethanol itself that elicits these potential ben-
eficial effects. Moreover, this medium-throughput analysis
of several hundred proteins (with the identification of two
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important species) points to the promise of proteomic
screening as a tool to better understand the pathophysio-
logical characterization of alcohol abuse and alcoholism.
PROTEOMICS APPLIED TO THE STUDY OF THE LIVER
Laura Beretta
With the completion of the genome project, the proteome
has been viewed as the next major challenge. There is a need
to begin an organized effort whose goals include developing
an infrastructure in proteomics that would substantially facil-
itate unraveling the complexity of the proteome in health and
disease. The Human Proteome Organization (http://www.h-
upo.org) was founded to regroup scientists in the public and
private sectors engaged throughout the world in various as-
pects of proteomics. The Human Proteome Organization has
outlined a mission for itself to (1) consolidate national and
regional proteome organizations into a worldwide organiza-
tion; (2) engage in scientific and educational activities to
encourage the spread of proteomics technologies and dissem-
inate knowledge pertaining to the human proteome and that
of model organisms; and (3) assist in the coordination of
public proteome initiatives aimed at comprehensively charac-
terizing specific tissue and cell proteomes. Initiatives currently
in the piloting phase include an international effort to identify
proteins detectable in normal serum and plasma and their
range of variation with age, ethnicity, and physiologic states
and a liver proteome initiative to identify proteins expressed
in the liver. These initiatives have attracted substantial interest
and will be integrated with efforts in protein informatics to
achieve data standardization on the one hand and data cura-
tion on the other. The strongest and most compelling argu-
ment for a liver proteome initiative is the essential and mul-
tifunction role of the liver in human health and disease. Liver
disease of some type affects more than 10% of the world
population. Liver pathogenesis remains, however, largely un-
defined, and most liver diseases remain poorly diagnosed,
staged, and treated. In addition, many proteins in plasma are
synthesized in the liver and change with disease in the liver, as
well as with systemic responses to inflammation and other
disease processes in other organs. Finally, protein signatures
in preclinical study models and in human liver samples could
be used as an effective way to understand pharmacology and
toxicology. Understanding the liver proteome will accelerate
the development of diagnostics and therapeutics toward the
diseases of this organ and also facilitate drug discovery. The
importance of liver proteomics research is reflected by the
commitment of countries worldwide to support in a major way
such an initiative. Scientific objectives of the human liver
proteome project include (1) a comprehensive analysis of
human liver protein constituents in health and disease, with an
initial focus on liver fibrosis and cancer; (2) bridging the liver
proteome project and the plasma proteome project to dis-
cover biomarkers; and (3) constructing a knowledge database
(integration and correlation of the human liver proteome with
the liver transcriptome and the human genome). Other topics
will include the determination of protein localization and
posttranslational modifications of the liver proteome, the sub-
cellular proteome, and networks of liver proteome. The im-
mediate goal for human liver proteome project (HLPP) is to
demonstrate what can be done in a pilot project. The key to
the pilot study is to find one that lays a foundation for future
studies. The proteome will be studied for the next 10 to 20
years or more. The hope is to stimulate that research now.
My group has recently applied proteomic technologies
for biomarker discovery. Hepatocellular carcinoma (HCC)
has a poor prognosis, with 5-year survival rates of less than
5%. Most cases of HCC are associated with cirrhosis, which
is commonly caused by alcohol intake, viral hepatitis, or
both. We combined two-dimensional polyacrylamide gel
electrophoresis and DNA microarray analysis to identify
genes and proteins that are potentially important in the
development and progression of hepatic carcinoma and
that are potential new markers for early cancer diagnosis.
Testing and validating these potential markers require
high-affinity probes for their detection and quantitation.
For this purpose, we are developing an antibody-based
microarray for the diagnosis of liver cancer through serum
assays. We also have recently implemented a proteomic-
based approach for the identification of tumor antigens
that induce an antibody response; we have applied this
approach to HCC. In contrast to approaches for identifi-
cation of tumor antigens on the basis of analysis of recom-
binant proteins, the proteomic approach we have used
allows identification of autoantibodies to proteins in lysates
prepared from tumors and tumor cell lines and thus may
more readily uncover antigenicity associated with post-
translational modification. We uncovered a distinct reper-
toire of autoantibodies that characterize the humoral re-
sponse in HCC. The detection of autoantibodies directed
against HCC-associated antigens we have identified may
have value for HCC screening, diagnosis, or follow-up.
SUMMARY
The study of proteins involved in alcoholism has involved
two different approaches. One approach, the “candidate
protein” approach, is to select a protein for study because
of its role in a pathway postulated to involve alcoholism.
Because alcoholism is a behavioral disorder, many of the
candidate proteins selected for study are involved in neu-
rochemical pathways. This is a legitimate approach that has
yielded significant results (e.g., Kasinathan et al., 1998). An
alternative proteomic, approach is to study as many pro-
teins as can be separated by a technique such as two-
dimensional gel electrophoresis and identified through
mass spectrometry. This approach does not select any can-
didate protein in advance as being important. Rather, this
approach incorporates the entire proteosome of the body.
In this workshop, Dr. Vrana presented some of the newer
proteomic methods that have been developed to separate and
identify proteins. Dr. Kasinathan and associates used a pro-
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teomic approach to identify urinary proteins that are excreted
by ethanol-treated rats, but not by control rats. One of the
proteins, transferrin, was observed in the urine of ethanol-
treated rats and not in that of the controls. Dr. Vrana and
colleagues demonstrated that high-density lipoproteins in se-
rum were increased in ethanol-treated macaques, which sug-
gests that this may be a mechanism for a beneficial conse-
quence of moderate ethanol intake. Dr. Beretta described the
Human Proteome Organization and its efforts to characterize
the liver proteome. This project may have important implica-
tions for researchers studying ethanol-induced liver disease.
The presentations given at the workshop give a glimmer of
what the future may hold. The new proteomic techniques
offer immense opportunities to study a large number of pro-
teins in a single preparation that may be influenced by alco-
holism. There is a saying that when the dust settles, we will
find out if we are riding a horse or an ass. It would be of
interest to have another meeting on proteomics and alcohol-
ism in a decade to see what has or has not been revealed.
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